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The metabolism of benzo[a]pyrene (BP)-4,5-oxide in 
the skin and liver of neonatal rats was studied after 
topical application of the arene oxide in vivo. The me-
tabolism of BP-4,5-oxide was time-dependent and 
showed a 2-h maximum for BP-4,5-dihydrodiol forma-
tion in both skin and liver. Product formation was also 
dose-dependent. Inhibitors of epoxide hydrolase such as 
clotrimazole, 1,1, 1 ,-trichloropropene oxide, and cyclo-
hexene oxide largely abolished the formation of BP-4,5-
dihydrodiol. The rapid biotransformation of arene ox-
ides such as BP-4,5-oxide in the skin emphasizes the 
potential importance of epoxide hydrolase in the acti-
vation and inactivation of polycyclic aromatic hydro-
carbons. Furthermore, the topically applied arene oxide 
also penetrated the skin and was rapidly metabolized in 
the liver as well. 
The skin is a n important interface between the body and the 
environment and can become a portal of entry for environmen-
tal pollutants, some of which can evoke toxicity including 
carc inogenicity in cutaneous tissue [1]. Benzo[a]pyrene is a 
ubiquitous environmental pollutant and is a known skin car-
cinogen [2] . It is generally accepted that polycyclic aromatic 
hydrocarbons (PAHs) such as BP, must be metabolically acti -
vated to dihydrodiol-epoxides which covalently bind nucleo-
philic sites on cellular macromolecules such as DNA to initiate 
t he process of carcinogenicity [2- 7] . Three successive enzy-
matic steps are involved in the generation of dihydrodiol-
epoxides of BP. First, turnover by the cytochrome P-450-
dependent monooxyge nase followed by epoxide hydrolase and 
again by mo nooxygenase [2,3,7- 10]. It follows that monooxy-
genases and epoxide hydrolase play important roles in the 
metabolism of P AHs. Also of importance is the availability of 
some as yet unidentified critical concentrations of reactive 
metabolites of PAHs in the target organ for the initiation of 
tumor induction. The balance between the ability of an organ 
to generate, detoxify, and eliminate reactive epoxide interme-
dia tes may be a critical factor in determining t he susceptibility 
or resistance of that organ to PAH -induced carcinogenesis. 
Therefore, deta iled studies on the mecha nism of these enzy-
matic pathways a re wa rranted in the skin. 
We have reported previously the presence of aryl hydrocar-
bon hydroxylase, several other monooxygenases, epoxide hy-
drolase, and glutathione-S-transferase activities in cutaneous 
t issue [11- 13). BP-4,5-oxide, a stable arene oxide, is a model 
substrate for the study of epoxide hydrolase and glutathione-
Manuscript received September 28, 1983; accepted for publication 
November 28, 1983. 
Supported in part by NIH Grant ES-1900 and research funds from 
the Veterans Administration. 
Reprint requests to: David R. Bickers, M.D., Director Dermatology, 
Veterans Administration Medical Center, 10701 East Boulevard, Cleve-
land, Ohio 44016. 
Abbreviations: 
BP: benzo[a]pyrene 
B P-4,5-clihydrodiol: benzof a]pyrene-4,5-trans-dihydrodiol 
BP-4,5-oxide: benzo[a]pyrene-4,5-oxide 
PAH: polycycl ic aromatic hydrocarbon 
TCPO: 1,1 ,1-trichloropropene oxide 
S-transferase activit ies [14- 16]. Furthermore, it is a weak mu-
tagen [17] and is relatively stable under physiologic conditions 
[18]. In this study we report that BP-4,5-oxide topically applied 
to neonatal rats is metabolized to BP-4,5-dihydrodiol and other 
water-soluble metabolites in the skin and liver. 
MATERIALS AND METHODS 
ChemicaL~ 
[G-'H]BP-4,5-oxide (sp act 282.5 mCi/mmol; radioc hemical puri ty 
greate r than 99%), chromatographically pure labeled BP-4,5-oxide, and 
BP-4,5-dihydrodiol were obta ined from the Midwest Research Institute 
(Kansas City, Missouri) through the Chemcial Repository of t he Na-
t ional Cancer Institute. Cyclohexene ox ide and 1,1,1- trichloropropene 
oxide (TCPO) were purchased from Aldrich Chemical Co. (Milwaukee, 
Wisconsin). Clotrimazole, 13-glucuronidase, D-saccharic ac id 1,4-lac-
tone, and aryl sulfatase were purchased from Sigma Chemical Co. (St. 
Louis, Missouri) . Whatman Linear-K silica gel TLC plates were ob-
tained from Fisher Scientific Co. (Cleveland, Ohio) . All solvents were 
of high-pressure liquid chromatography grade and were purchased from 
Burdick and Jackson Laboratories, Inc. (Muskegon, Michigan). 
Animals 
Sperm-posit ive Sprague-Dawley rats of known insemination date 
were obtained from the Holtzman Rat Farm (Madison , Wisconsin). 
Neonatal rats born in situ were allowed to suckle until the 4th day 
after birth, withdrawn from their mothers, and used in the experiments. 
The animals' weight at the time of the experiment ranged from 9.5-
10.5 g. The advantages of using neonata l rodents for studies on cuta-
neous drug metabolism have been described previously [ll]. 
Treatment of Animals 
The animals were treated topically with ["H]BP-4,5-oxide (180 
nmol/10 g body wt in 100 ILl of acetone) and sacri ficed at 0, l, 2, 6, and 
24 h afte r dosing for the time-dependent experiment. For the dose-
dependent study, t he rats were treated topically with 36, 90, 180, 360, 
540, and 720 nmol ['1H]BP-4,5-oxide per 10 g body wt 2 h prior to 
sacrifice. In the studies where the effects of various inhibitors were 
swdied, the animals were t reated topically wi th single applications of 
cyclohexene ox ide (2 mg/10 g), TCPO (2 mg/10 g), or clotrimazole (2 
mg/10 g) 24 h prior to sacrifice. All an imals were t hen t reated with a 
single topical application of ["H]BP-4 ,5-oxide (180 nmol/10 g) 2 h prior 
to sacrifice. The an imals were killed by decapitation and the skin and 
liver removed. All subsequent operations were carried out at 0- 4 "C. 
The skin and liver were then minced with scissors in 0.1 M phosphate 
buffer pH 7.4. The minced t issue was homogenized wit h 6 separate 
bursts of a Polytron T issue Homogenizer (Brinkman Instruments, 
Westbury, New York) equipped with an ST-10 generator. 
Isolation and Analysis of BP-4,5-oxide Metabolites 
BP-4,5-dihydrodiol and water-soluble metaboli tes were analyzed in 
extracts prepared from the skin and liver homogenates. Tissue homog-
enates were extracted 3 t imes with 2 volumes of ethyl acetate:acetone 
(2:1, v/ v). The organic and aqueous phases were separated by centri f-
ugation and t he organic residue dried under a stream of nitrogen and 
t hen dissolved in 2 ml of methanol for thin-layer chromatographic 
analys is. The method for TLC separation of BP-4,5-oxide and BP-4,5-
dihydrodiol has been described earlier [19,20]. Aliquots (0.1 ml) were 
applied to TLC plates and developed in tanks containing ben-
zene:ethanol (95:5, v/v). BP-4,5-oxide and BP-4 ,5-dihydrodiol on the 
plates were identified on t he basis of reference standards. The R1 of 
BP-4 ,5-oxide under the conditions of chromatography was 0.9, while 
the R1 of BP-4,5-dihydrodiol was 0.2- 0.3. After development, the plates 
were air dried, and BP-4 ,5-dihydrodiol and BP-4,5-oxide were quanti-
fied by countin g samples scraped from TLC plates on a Packard 
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TriCarb 460CD liquid scintillation spectrometer. Aliquots of the 
aqueous phase were also counted to determine the amount of water-
soluble metabolites present. 
Aqueous samples were analyzed further for the presence of glucu ro-
nide and sulfate conjugates of the dihydrodiol as described by Di -
Giovann i et al [21]. For the determination of glucuronide conjugates, 1 
ml of the aqueous sample was combined with 1 ml of 0.1 M potassium 
phosphate buffer pH 6.8 and incubated at 37"C for 2 h with 2000 
Fishman units {:l-glucuronidase per mi. The addition of 20 mM o-
saccharic acid 1,4-lactone completely inhibited the release of glucuro-
nide conjugates under these condit ions. In addition, ascorbic acid (1 
mg/ml) was routinely added to incubations to prevent any spontaneous 
oxidation. For the determination of sulfate conjugates, 1 ml of the 
aqueous sample was combined with 1 ml of 0.2 M sodium acetate buffer 
pH 5.0 and incubated at 37"C for 4 h with aryl sulfatase (30 units/ml) 
plus 20 mM o-saccharic acid 1,4-lactone. After incubation, the reactions 
were terminated by adding 2 volumes of ice-cold ethyl acetate:acetone 
(2: 1, v/v). Samples were then centrifuged, and the organic phase was 
counted for radioactivity, a blank for each sample containing all reac-
tants except enzyme was employed and the values obtained were 
subtracted from the appropriate sample. 
RESULTS 
Time and Dose Dependent Metabolism of BP-4,5-oxide by the 
Neonatal Rat 
A single topical application of BP-4,5-oxide to neonatal rats 
resulted in the formation of BP-4,5-dihydrodiol as well as 
water-soluble metabolites. The data in Table I indicate that 
the metabolism of BP-4,5-oxide to BP-4,5-dihydrodiol by the 
rat skin is time-dependent. The formation of BP-4,5-dihydro-
diol in liver as well as in skin was maximum at 2 h after topical 
application of BP-4,5-oxide to rats. However, substantia l 
amounts of BP-4,5-dihydrodiol were recovered even 24 h fo l-
lowing a single topical application of BP-4,5-oxide. The for-
mation of BP-4,5-dihydrodiol in liver was always higher (2-6 
times) than that occurring in the skin. Within minutes (0 h) 
after topical application of BP-4,5-oxide the amount of dihy-
drodiol recovered from the liver was 1.3 times that of the skin; 
at 1, 2, 6, and 24 h after dosing this was 1.8-, 6.1-, 6.4-, and 3.0-
fold higher, respectively. A similar trend for time dependency 
was observed in the formation of water-soluble metabolites of 
topically applied BP-4,5-oxide in the liver and skin (Table I). 
Increasing concentrations of BP-4,5-oxide applied topically 
to t he skin of neonatal rats resulted in a linear increase in the 
recovery of BP-4,5-dihydrodiol (Fig 1). The largest increment 
in diol formation occurred between doses of 180 and 360 nmol/ 
animal. There was approximately 50% more dihydrodiol formed 
at t he 360-nmol dose than at t he 180-nmol dose (Fig 1). 
Metabolism of BP-4,5-oxide to Glucuronide and Sulfate 
Conjugates by N eonatal Rat Skin 
The water-soluble metabolites obtained after ethyl acetate 
extraction were enzymatically digested with ,6-glucuronidase 
TABLE I. Time-depen.di!nt metabolism of topically applied BP-4.5-
oxide in neonatal ra.t shin and liver 
BP-4,5-dihydrodiol W mer-soluble metabolite 
Time• formation (n mol/an imul) formation (nmol/animal) 
(h) 
Skin' Liver Skin Liver 
0 1.6 ± 0.2'" 3.0 ± 0.2 3.7 ± 0.4 16.0 ± 0.8 
1 4.1 ± 0.1 7.4 ± 0.4 14.4 ± 0.6 23.9 ± 1.1 
2 7.7 ± 0.3 47.2 ± 1.4 15.1 ± 0.6 26.4 ± 1.4 
6 5.2 ± 0.2 33.2 ± 1.1 9.6 ± 0.3 25.2 ± 1.2 
24 4.8 ± 0.2 14.4 ± 0.8 8.2 ± 0.3 13.6 ± 0.7 
• For each time point determination 4 animals were treated topically 
with ["H]BP-4,5-oxide (180 nmol/animal) and sacrificed at the speci-
fied time intervals. 
b Skin and liver homogenates were prepared and the organic solvent-
extractable material was applied to TLC plates as described in Mate-
rials and M ethods. The aqueous phase remaining after organic extrac-
tion contained the water-soluble metabolites. 
<Mean ± SEM of 4 experiments. 
0 200 400 600 
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FIG 1. Dose-dependent metabolism of BP-4,5-oxide in rat skin . 
Neonatal rats (9.5-10.5 g body wt) were topically treated with various 
concentrations of l"H]BP-4 ,5-oxide and sacrificed 2 h after dosing. 
Data represent mean ± SEM of 4 separate experiments. 
TABLE II. Water- soluble metabolism of BP-4,5-oxide by neonatal rat 
skin. 
Conjugat-e" 
BP-4,5-dihydrodio l-{3-
glucuronide 
BP-4,5-dihydrodiol -
sulfate 
I"H I BP-4,5-dihydrodiol-
conjugate' 
(pmol/ ml) 
20.2 ± 0.8' 
24.4 ± 1.1 
Percent of 
tot.a l aqueous 
phase 
0.12 
0.18 
"Neonatal rats were treated topically with ["H]BP-4 ,5-oxide (180 
nmol/ animal) 2 h prior to sacrifice. Skin homogenates were prepared 
and extracted 3 times with ethyl acetate. The aqueous phase was then 
treated with either {:l-glucuronidase (2000 units/ ml) and 20 mM o-
saccharic ac id 1,4-lactone or aryl sulfatase (30 uni ts/ml) and 20 mM o-
saccharic acid 1,4 -lactone. These reaction mixtures were incubated at 
37"C for 2- 4 h. 
b Organic extracts were counted to determine the amount of ['1H]BP-
4,5-dihydrodiol bound to conjugate. 
,. Mean ± SEM of 4 experiments. 
and aryl sulfatase. The formation of BP-4,5-dihydrodiol-,B-
glucuron ide and sulfate conjugates in neonatal rat skin are 
depicted in Table II. Dihydrodiol conjugation with glucuronide 
and sulfate represents only a fraction of the total aqueous 
metabolism of the hydrocarbon . Less than 1% of the aqueous 
metabolites were conjugated with glucuronide and sulfate (Ta-
ble II). 
Inhib ition of BP-4,5-dihydrodiol Formation by Epoxide 
Hydrolase Inhibitors in the Skin 
To further verify that the formation of BP-4,5-dihydrodiol 
from BP-4,5-oxide in neonatal rat skin occurred enzymatically, 
several known inhibitors of epoxide hydrolase were evaluated. 
Animals treated topically with cyclohexene oxide, TCPO, or 
clotrimazole showed significant reduction in BP-4,5-dihydro-
diol formation (Fig 2). Cyclohexene oxide, TCPO, and clotri-
mazole reduced the level of dihydrodiol formation by 51, 56, 
and 72% respectively. 
DISCUSSION 
The data presented here indicate that topical application of 
BP-4,5-oxide to skin resulted in the metabolic conversion to 
BP-4,5-dihydrodiol and to water-soluble metabolites and con-
jugates. BP-4,5-dihydrodiol formation was maximum at 2 h, 
after which there was a gradual decrease in the amount of BP-
4,5-dihydrodiol formed. The decrease in the formation of the 
dihydrodiol after 2 h may relate to its binding to macromole-
cules such as DNA, RNA, and protein . The decrease in water-
soluble metabolites after 2 h may be due to the detoxification 
and excretion c.f conjugated metabolites. Our data also suggest 
a linear increase in BP-4,5-dihydrodiol formation as a function 
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FIG 2. Inhibit ion of the metabolism of BP-4,5-oxide to BP-4,5-
dihydrodiol in rat skin. Neonatal rats (9.5- 10.5 g body wt) were topi-
cally treated with acetone (control) , cyclohexene oxide (2 mg/animal), 
TCPO (2 mg/animal), or clotrimazole (2 mg/animal) 24 h prior to 
[3H]BP-4,5-oxide application. All animals were then topically treated 
with [31-l]BP-4,5-oxide (180 nmol/animal) 2 h before sacrifice. Data 
represent mean ± SEM of 4 separate experiments. 
of increasing BP-4,5-oxide concentration after topical applica-
t ion to the skin. 
The formation of water-soluble conjugates in neonatal rat 
skin was also observed in this study. We found very limited 
a mounts of both glucuronic and sulfuric acid conjugates 2 h 
a fter topical application of BP-4,5 -oxide. This may be due to 
the limited amount of substrate present in the skin. The 
presence of glucuronide and sulfate conjugates of BP-4,5-c:li -
hydrodiol in vitro [22,23] and in isolated perfused organ stuc:lies 
[24,25] has been shown previously. The formation of t hese 
conjugated metabolites of arene oxides in skin has not previ-
ous ly been demonstrated. 
Our data also indicate that the metabolism of BP-4,5-oxide 
to BP-4,5-dihydrodiol in skin is enzyme-mediated since several 
inhibitors of epoxide hydrolase [26] largely abolished the for-
mation of BP-4,5-dihydroc:liol in t he skin. The imidazole anti-
fungal agent clotrimazole was the most effective inhibitor in 
t his respect. C lotrimazole has previously been shown to be a 
potent inhibitor of t he cytochrome P-450-dependent microso-
mal enzyme a ryl hydrocarbon hydroxylase [27]. Our unpub-
lished observations have suggested that clot rimazole is also a 
potent inhibitor of microsomal epoxide hydrolase in vitro. 
In summary, our data indicate that the topically applied 
model arene oxide, BP-4,5-oxide, is metabolized to BP-4,5-
dihydrodiol and to sulfate and glucuronide conjugates in rat 
skin . Furthermore, topically applied BP-4,5-oxide was shown 
to be rapidly metabolized in t he liver, suggesting that the skin 
exposure to some carcinogenic compounds may result in per-
cuta neous absorption of the parent compound and/or its me-
tabolites which in t urn could produce effects in other body 
tissues. 
The authors thank Mrs. Sandra Evans for typing the manuscript. 
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